Effect of Additional Ecabet Sodium on Conventional Triple Therapy for Helicobacter pylori Eradication in Korea / 대한소화기내시경학회지
Korean Journal of Gastrointestinal Endoscopy
;
: 349-355, 2011.
Article
in Korean
| WPRIM
| ID: wpr-78846
ABSTRACT
BACKGROUND/AIMS:
Ecabet sodium is known for its bactericidal effect against H. pylori. It was reported that a supplement of ecabet sodium to conventional triple therapy showed good results in Asia. The Aim of this study was to ascertain the efficacy of additional ecabet sodium on conventional triple therapy for eradication of H. pylori.METHODS:
We reviewed the cases of 111 patients (Group A) with H. pylori infection who received ecabet sodium with triple therapy (20 mg of rabeprazole, 1 g of amoxicillin, 500 mg of clarithromycin and 1 g of ecabet sodium, twice daily for 7 days). Another 186 patients (Group B) received PPI-based triple therapy (same as the above, except without the ecabet sodium). Eradication was evaluated 4 weeks later after completion of treatment by 13C-UBT.RESULTS:
Eradication rates were 74.8% (83/111) in group A and 70.4% (131/186) in group B by intention-to-treat analysis (p=0.420), and 75.2% (82/109) in group A and 70.7% (128/181) in group B by per protocol analysis (p=0.405).CONCLUSIONS:
The addition of ecabet sodium to conventional triple therapy did not increase the eradication rate of H. pylori in this study. These findings imply that ecabet sodium as an additional agent cannot overcome antibiotic resistance, which is the most important cause of failure of triple therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Asia
/
Sodium
/
Drug Resistance, Microbial
/
Helicobacter pylori
/
Helicobacter
/
Clarithromycin
/
Abietanes
/
2-Pyridinylmethylsulfinylbenzimidazoles
/
Amoxicillin
/
Korea
Type of study:
Practice guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Korean Journal of Gastrointestinal Endoscopy
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS